AIDA ONCOLOGY

Despite massive investment in oncology over the last 30 years, the efficacy of cancer treatments remains stubbornly low. Positive response rates of c.25% (i.e., only 1 in 4 patients) that receive a drug, will benefit from it are typical. New drugs are still being approved with response rates lower than this. Aida will transform the treatment of cancer by increasing the positive response rates to more than 50%. Aida can deliver this via our proprietary algorithmic approach to tumor transcriptome analysis, allowing us to predict a patient’s response to a drug. By predicting on multiple drugs (from one biopsy), we can identify the drugs most likely to have a positive response and enable the doctor to choose the most effective treatment.